Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial

Three years after gaining three liver disease assets in its $952 million buyout of Alb | Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop the trio. The company has reported the failure of liver disease drug Bylvay in a phase 3 study in biliary atresia.